Evidence map›Paper›PMID 36560452›Full record

ArticleVaccines2022

Engagement of the G3BP2-TRIM25 Interaction by Nucleocapsid Protein Suppresses the Type I Interferon Response in SARS-CoV-2-Infected Cells.

Zening Yang, Jing Li, Jiali Li, Huiwen Zheng, Heng Li, Qingrun Lai, Yanli Chen, Li Qin, Yuanyuan Zuo, Lei Guo and 2 more

Open access · goldAbstract read
In one paragraph

Article in Vaccines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Zening YangChinese Academy of Medical Sciences, Key Laboratory of Virus Vaccine Research & Development System Innovation, Institute of Medical Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Kunming 650031, China.
Jing LiChinese Academy of Medical Sciences, Key Laboratory of Virus Vaccine Research & Development System Innovation, Institute of Medical Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Kunming 650031, China.
Jiali LiChinese Academy of Medical Sciences, Key Laboratory of Virus Vaccine Research & Development System Innovation, Institute of Medical Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Kunming 650031, China.
Huiwen ZhengChinese Academy of Medical Sciences, Key Laboratory of Virus Vaccine Research & Development System Innovation, Institute of Medical Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Kunming 650031, China.
Heng LiChinese Academy of Medical Sciences, Key Laboratory of Virus Vaccine Research & Development System Innovation, Institute of Medical Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Kunming 650031, China.ORCID 0000-0002-6352-2469
Qingrun LaiChinese Academy of Medical Sciences, Key Laboratory of Virus Vaccine Research & Development System Innovation, Institute of Medical Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Kunming 650031, China.
Yanli ChenChinese Academy of Medical Sciences, Key Laboratory of Virus Vaccine Research & Development System Innovation, Institute of Medical Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Kunming 650031, China.
Li QinChinese Academy of Medical Sciences, Key Laboratory of Virus Vaccine Research & Development System Innovation, Institute of Medical Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Kunming 650031, China.
Yuanyuan ZuoChinese Academy of Medical Sciences, Key Laboratory of Virus Vaccine Research & Development System Innovation, Institute of Medical Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Kunming 650031, China.
Lei GuoChinese Academy of Medical Sciences, Key Laboratory of Virus Vaccine Research & Development System Innovation, Institute of Medical Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Kunming 650031, China.ORCID 0000-0003-1733-1802
Haijing ShiChinese Academy of Medical Sciences, Key Laboratory of Virus Vaccine Research & Development System Innovation, Institute of Medical Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Kunming 650031, China.
Longding LiuChinese Academy of Medical Sciences, Key Laboratory of Virus Vaccine Research & Development System Innovation, Institute of Medical Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Kunming 650031, China.ORCID 0000-0002-1870-0035
Chinese Academy of Medical Sciences & Peking Union Medical College · CN

Funding

National Natural Science Foundation of China 32070923National Natural Science Foundation of China 81373142
6 · The paper itself

Abstract

The nucleocapsid (N) protein contributes to key steps of the SARS-CoV-2 life cycle, including packaging of the virus genome and modulating interactions with cytoplasmic components. Expanding knowledge of the N protein acting on cellular proteins and interfering with innate immunity is critical for studying the host antiviral strategy. In the study on SARS-CoV-2 infecting human bronchial epithelial cell line s1(16HBE), we identified that the N protein can promote the interaction between GTPase-activating protein SH3 domain-binding protein 2 (G3BP2) and tripartite motif containing 25 (TRIM25), which is involved in formation of the TRIM25-G3BP2-N protein interactome. Our findings suggest that the N protein is enrolled in the inhibition of type I interferon production in the process of infection. Meanwhile, upgraded binding of G3BP2 and TRIM25 interferes with the RIG-I-like receptor signaling pathway, which may contribute to SARS-CoV-2 escaping from cellular innate immune surveillance. The N protein plays a critical role in SARS-CoV-2 replication. Our study suggests that the N protein and its interacting cellular components has potential for use in antiviral therapy, and adding N protein into the vaccine as an antigen may be a good strategy to improve the effectiveness and safety of the vaccine. Its interference with innate immunity should be strongly considered as a target for SARS-CoV-2 infection control and vaccine design.

Indexed as

G3BP2nucleocapsid proteinRIG-I-like pathwaySARS-CoV-2TRIM25

Identifiers

PMID36560452
PMCPMC9781323
OpenAlexW4311160596

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.